Probably run up to FDA decision in April 2024.

PharmaTher Provides Update of its Priority Original Abbreviated New Drug Application for Ketamine
https://finance.yahoo.com/news/pharmather-provides-priority-original-abbreviated-130000660.html

Fabio Chianelli, CEO of PharmaTher, commented: “We believe 2024 will be a transformative year for PharmaTher with the expected FDA approval of ketamine having an assigned goal date for approval on April 29, 2024. In anticipation of a potential FDA approval, we are focusing on the commercial scale-up of ketamine in the U.S. and seeking additional international approvals.”

Shareholder Letter
February 13, 2024

To: Our Valued Stockholders:
We are pleased to present to you the comprehensive overview of PCT LTD’s performance and strategic
direction for the fiscal years ending 2023 and 2024. It has been a year of significant achievements,
marked by decisive actions and strategic focus. As we navigate the ever-evolving landscape of industries
we serve, we are confident in our trajectory and the opportunities that lie ahead.

Throughout 2023, PCT LTD underwent a transformative journey, streamlining operations to ensure
sustained profitability and focusing on core divisions that drive our growth. We bade farewell to our
Healthcare division in May 2023, redirecting our resources towards our other two divisions: Paradigm
Convergence Technologies (PCT) and 21st Century Energy Solutions (21CES).

PCT’s primary revenue streams remain centered around two core objectives. Firstly, we continue to
manufacture and distribute anolyte and catholyte fluid producing equipment, catering primarily to the
Oil and Gas industry through 21CES. Secondly, we supply anolyte and catholyte fluids to diverse sectors
including healthcare, agriculture, hospitality, and governmental entities.

In the fourth quarter of 2023, we expanded our distribution network, onboarding two new distributors,
with two more joining us in 2024. Our distributor’s focus on key industries such as agriculture and
healthcare has bolstered our market presence while ensuring sustained growth.

Despite the divestment of our Healthcare division, we uphold our commitment to our existing contracts,
exemplified by our continued service provision to a hospital in Nevada.

Looking ahead, our focus remains on sustainable growth. We are actively recruiting and onboarding
distributors to diversify revenue streams while enhancing marketability across multiple sectors, including
Agriculture, Healthcare, Hospitality and beyond.

21st Century Energy Solutions (21CES) remains committed to its partnerships within the Oil industry,
operating depot facilities in Texas and Oklahoma. Our facilities boast significant production capacities,
which enable us to meet the demands of our clients efficiently. Additionally, we continue to explore
opportunities to expand our depot facilities to better serve both the Energy and Agriculture sectors.

A notable highlight from 2023 includes the success story of our partnership with Fairview Productions,
where our treatments led to a substantial increase in well production. This partnership underscores our
commitment to delivering tangible results for our clients.

Our pipeline of opportunities continues to grow steadily, with promising prospects across various
regions. We have established a robust decision process, starting with internal testing, followed by pilot
programs, leading to full-scale treatments upon successful completion.

As we reflect on our achievements and look toward the future, we are excited about the prospects that
2024 holds for us. With a solid foundation, an expanding market presence, and a commitment to
innovation, PCT LTD is well positioned for continued success.

We extend our sincere gratitude to our shareholders for their unwavering support and confidence in our
vision. Together we will navigate the challenges and seize the opportunities that lie ahead.

Art Abraham
President & CFO
https://pctl.com/wp-content/uploads/2024/02/2023-Shareholder-Letter.pdf#new_tab

Volume exceeded average by over 700,000 shares.

Bioelectronics Chairman Updates Investors

https://stockhouse.com/news/press-releases/2024/02/15/bioelectronics-chairman-updates-investors

I like investing long in penny stocks and I have noticed they are not so popular anymore, but when good news hits they can still go up big. They don't attract as many flippers either so they don't dump as fast as they used to do. Just have pick good ones and stay patient.

Me too!

Added another 20000 shares at .0041. A steal at this price!

Here is a well we recently treated. Initially 1/2 barrel of oil to 3 barrels of water. After treatment with our proprietary Anolyte and Catholyte, and being shut in for 8 days, the well is now producing 2-3 barrels of oil with no water! #OOTT #oilandgas #drilling
https://t.co/vCqKegW3FT
21st Century-Energy@21stEnergy

Here is a well we recently treated. Initially 1/2 barrel of oil to 3 barrels of water. After treatment with our proprietary Anolyte and Catholyte, and being shut in for 8 days, the well is now producing 2-3 barrels of oil with no water! #OOTT #oilandgas #drilling pic.twitter.com/vCqKegW3FT

— 21st Century-Energy (@21stEnergy) December 12, 2023

Enjoy your island vacation. Here's an update on the sp: Business Warrior Corp BZWR:OTC Pink - Current Information OTC

Quote Information Table
Last Price Today's Change Bid/Size Ask/Size Today's Volume
$0.0065 +0.0004 (6.56%) $0.0059/23,505 $0.0075/22,750 94,000 Above Avg.
As of 1:55 PM ET, 12/12/2023

Here's a video just for you the investor for a little entertainment while you're waiting:
https://community.snakesandlattes.com/post/new-welcome-video-for-funn-shareholders-12782232?pid=1336388463

BRAINSTORM CELL THERAPEUTICS INC.
Annual Meeting of Stockholders

https://east.virtualshareholdermeeting.com/vsm/web?pvskey=BCLI2023AM

BRAINSTORM CELL THERAPEUTICS INC. is hosting a Virtual Stockholder Meeting on Monday, December 18, 2023 at 10:00 AM, Eastern Time, and the stockholders of record will be able to vote and ask questions online during the meeting. If you would like to attend the virtual meeting and have your control number, please log in 15 minutes prior to the start of the meeting.

To the Stockholders of Brainstorm Cell Therapeutics Inc.:
Notice is hereby given that the December 2023 Annual Meeting of Stockholders (the “Meeting”) of
Brainstorm Cell Therapeutics Inc. (the “Company”) will be held on December 18, 2023 at 10:00 a.m.,
Eastern time, virtually via the internet at central.virtualshareholderm..., for the
following purposes

BRAINSTORM CELL THERAPEUTICS INC.'s Virtual Shareholder's Meeting - Pre meeting message page
https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=317853002&type=PDF&symbol=BCLI&cdn=149521fc0e34b68e67d975b2a1a58943&companyName=Brainstorm+Cell+Therapeutics+Inc.&formType=DEF+14A&dateFiled=2023-11-08

Form NT 10-K Business Warrior Corp For: Aug 31
4:47 PM ET, 11/29/2023 - US Securities and Exchange Commission
http://archive.fast-edgar.com/20231129/AQZWCG2CZ22FHZQZ2K2Q2ZZ2HD7QZZ28Z252

Filed on: November 29, 2023

Maverick Energy Group, Ltd. and Willcox International Holdings, Inc. Form Joint Venture for Lithium Extraction from Saltwater Brine in Oil Production

ST. AUGUSTINE, FL / ACCESSWIRE / November 30, 2023 / Maverick Energy Group, Ltd. (OTC PINK:MKGP) is excited to announced the formation of a Joint Venture with Willcox International Holdings, Inc. to exploit opportunities to extract Lithium from saltwater brine in oil production. Willcox through its partnership with NeoLithica LTD, which maintains operations in Alberta, Canada, will use its Direct Lithium Extraction Technologies to extract lithium from brine.

In their efforts to expand their Lithium Projects beyond Canada, Willcox will begin testing oil field brines made available by Maverick in several potentially high lithium concentration areas. Located primarily in the Smackover Formation, as well as the Texas and Oklahoma panhandle, the geographic regions of Maverick's holdings are known for containing high, commercially viable concentrations of Lithium. Wilcox will be using the environmentally friendly direct lithium extraction method (DLE) to produce lithium and then refine the product into battery grade lithium carbonite.

The current environment for permitting and funding for lithium mining were greatly improved with the passing of "The Inflation Reduction Act" and it has heightened interest from large oil companies, such as Exxon (NYSE: XOM) and their recently announced Southern Arkansas lithium project. The Act's focus with lithium is to increase the domestic production of lithium and make batteries with generous tax credits and other incentives.

Saeb Jannoun, CEO of Willcox, stated "we believe this venture between Willcox and Maverick will prove to be very lucrative for both of our companies. The field which we will be testing has been proven to contain high concentrations of lithium and we hope to begin production in the coming months. The Company's plan to start testing brine samples over the next few weeks."

"This partnership with Willcox, will task Maverick to find and evaluate both oil and gas properties for acquisition and saltwater sources that contain acceptable levels of lithium to be acquired and developed by the Joint Venture. With Willcox's technical expertise and financial resources and Maverick's industry knowledge and relationships both companies should see a rapid increase in profitability and cash flow.," said James McCabe CEO Maverick.

About Willcox International Holdings Inc. (WINH)

WINH, has been focused on the green energy sector and the development of renewable energy resources. In addition to the company's efforts in Canada, the company has been in talks to develop lithium extraction projects as well as battery production technology in the United States and Middle East North Africa countries (MENA). WINH has had several on the ground meeting in these countries over the past year and intends to establish a permanent presence in the Arabian Gulf. The renewable energy sector has rapidly gained traction and momentum in these countries as the global focus has shifted to Electric Vehicles (EV) rather than carbon consuming transportation.

About Maverick Energy Group, Ltd. (MKGP)

Maverick Energy Group LTD is a crude oil and natural gas acquisition, production, exploration, and horizontal drilling development company focusing on select areas of North America. Maverick believes that its license to patented and proprietary horizontal production enhancement technologies facilitate the rapid accumulation of valuable oil and gas assets, while at the same time greatly improving the rate of production and lifetime potential of these properties.

Diana - I was well aware that you had already posted the CEO's comments. Apparently you do not take him at his word. I find him to be a man of integrity and good character and trust his statements. That's my DD and why I am still buying at this price.

Here's the results:
On the business front…
✅ Marketing - ROAS is profitable & scalable
✅ Sales - Solid closing ratios & offers are working
✅ Product: Feedback from clients tells us we built the right product at the right time
✅ Revenue: Growing & getting closer to our goal of profitability

Lots of promotional information posted by Business Warrior on Twitter in November highlighting PayPlan features.
PayPlan features

What happens to our investment if it reaches No Bid?

Well...I care. I cared enough to go to PCTL's website and send a request to the company for a confirmation of the podcast. After you thank me, you can thank jobynimble for posting the notification before me on iHub. Now I guess you can blame the company for not caring enough to advertise the podcast more widely than just on Twitter. Happy now?

Podcast confirmation

Tue 10/3/2023 11:21 AM

Confirming the podcast on Thursday, October 5th, in the afternoon. Will post on Twitter once the podcast is available, currently we do not have a confirmed time.

PCT Corp
(843) 390-7900
info@pctl.com
www.pctl.com
4235 Commerce Street, Little River, SC 29566
A New Disruptive Technology in the World of Disinfection. Visit us at www.pctl.com

Update on Twitter from 21st Century Energy:

21st Century-Energy
@21stEnergy
Just an update: The well that was treated nearly a year ago in Murray, OK is producing 25 barrels a day (still WAY up from the pre-treatment of 5 barrels a day). The second well has been drilled, with completion expected next week!

Annual Report out! https://www.otcmarkets.com/otcapi/company/financial-report/383017/content

Last year's reported that "SNAKES & LATTES INC. (OTC: FUNN) is Pleased to Report an Almost 200% Increase in Year Over Year FY22 Revenue at $6,064,896, up From $2,027,988 for FY21, With Gross Profits up From $1,369,514 to $4,223,022". September 27 2022 - InvestorsHub NewsWire

I hope you averaged down during those 5 years. If not, you would be down 94%!

Great report! Case study shows meaningful results against harmful impact of fungus and insects on cannabis crops. Very promising!

Article posted by moonboy: Tollovid is discussed in the Targeted Supplementation section about 2/3 of the way down the article.

The Five Drivers of Long COVID


Les, did you even read the article? If you did, you would know that the number of lines describing Tollovid are irrelevant to judging the importance of Tollovid. This article describes an overview of a recent study: "Over the last year, a working group of functional medicine practitioners came together to review the world’s literature, compare clinical experiences, and lay groundwork for a comprehensive therapeutic approach to Long Covid." To show its emphasis it is titled "The Five Drivers of Long COVID". Most of the article elaborates on assessment of COVID and discussion of the "the five physiological drivers in the transition from acute to long Covid".

Treating Long COVID is introduced at the end as requiring a complex approach, not just a "magic bullet". "Restoring health in the wake of SARS-CoV-2 requires a carefully-tailored, long-term, multimodal approach that includes diet and lifestyle changes, attention to sleep hygiene and stress mitigation, movement and exercise, and intensive nutritional support."

When it gets around to mentioning Specialty Supplements used for treatment, Tollovid is the first one of only two supplements described: This short list "includes some new and unique products, like Tollovid (Todos Medical)—a compound derived from Lithospermum erythrorhizon, an Asian medicinal plant. It binds the 3CL protease that many RNA viruses produce to cleave their RNA. In so doing, it inhibits viral replication, thus targeting the Viral Persistence driver." Anyone who reads the article looking for a Specialty Supplement to treat Long COVID is likely to google Tollovid to find more information about it.

I find the article important for Tollovid because it comes from a reputable source and provides a reasoned analysis of the problem of Long Covid which concludes by introducing Tollovid and its mechanism of action for treatment.

I took advantage of the dip to buy more at 2.08!

According to TDAmeritrade the current volume for CNNA is 1,483,500 (Heavy Day). The 10-day average volume is 296.1K. Just so you will know.

Someone just spent 15 cents to bring back up to .0005? What a circus this is!

PCTL
Price
$0.0032
Day's Change
0.0009 (39.13%)
Bid
0.0022
Ask
0.0032
B/A Size
22700x824115
Day's High
0.0032
Day's Low
0.0021
Volume(Light)
660,100
June 30, 2023 3:20pm ET

How's this for communication?

https://www.otcmarkets.com/stock/FUNN/news/SNAKES--LATTES-INC---Q3-FY2023-POSTS-CONTINUED-STRONG-GROWTH?id=400783

SNAKES & LATTES INC. - Q3 FY2023 POSTS CONTINUED STRONG GROWTH
Press Release | 05/15/2023
SNAKES & LATTES INC. (OTC: FUNN), owner and operator of the first and largest board game entertainment venues in North America specializing in full-service bar / restaurant offerings, today announced financial results for the quarter ended March 31, 2023 (Q3 FY2023).

Key Third Quarter Fiscal Year 2023 Highlights (All numbers are in USD)

Revenue of $2,402,274 for the quarter, an increase of $905,065 or 60.45% compared to Q3 FY2022 and an increase of 226.35% compared to Q3 FY2021

Acquired a new Brick & Mortar gaming location in Virginia Beach VA in early March 2023

Record quarter for the Tempe, Chicago, Tucson, Provo and Midtown locations.

Best quarter since COVID for the College and Annex locations.

Security Details & Shareholders Equity

No Change in the Outstanding Share Count (Since Apr. 27, 2022)

No New Convertible Notes Issued (Since Feb. 22, 2021)

No Change in the Public Float (Since June 2, 2022)

Snakes & Lattes Inc. is proud to announce another great quarter of increasing revenues. Walk-in sales across the board are increasing throughout all locations in the USA and Canada. Our focus on hosted retail and corporate events has also continued to receive a very positive reaction. These factors combined with our newest Virginia Beach location has allowed the company to report yet another strong quarter of increasing revenues and annual growth. said Snakes & Lattes founder Ben Castanie. It is a very exciting time! The Snakes & Lattes Tempe, Chicago, Tucson, Provo and Midtown locations all experienced a record-breaking quarter while the College and Annex locations both had their best quarter since COVID. Industry momentum we are experiencing is at an all time high. The sheer amount of business interest in Snakes & Lattes is keeping us non-stop with our expansion efforts and we are excited to bring our shareholders and the investment community at large future positive announcements of the ongoing initiatives being worked on behind the scenes as they materialize and unfold.

Key Third Quarter Fiscal Year 2023 Metrics (All numbers are in USD)

Cash on Hand is up 230.3% to $176,452
Accounts Receivable is up 115% to $67,866
Accounts Payable is down 10.41% to $2,770,601
Total Assets are up 8% to $4,203,084
Short Term Debt is up 2.7% to $2,550,857
Long Term Debt is down 45.3% to $494,051
Non-Current Liabilities is up 3.38% to $794,532
Total Liabilities is up 5.88% to $9,600,545


Q3 FY2023 Report Available

All Company financial reports can be viewed at the following link:

https://www.otcmarkets.com/stock/FUNN/disclosure





About Snakes & Lattes Inc.

Snakes & Lattes Inc. founded the first and largest board gaming entertainment venues in North America with the largest circulating public library of board games in the world for players to choose from. Snakes & Lattes Inc. gaming locations also specialize in full-service bar / restaurant offerings and currently own and operate 8 locations throughout the USA and Canada. Locations include Tempe and Tucson Arizona, Chicago Illinois, Provo Utah, Virginia Beach Virginia, as well as 3 locations in Toronto, Ontario, Canada.

Snakes & Lattes Inc. is continuously in processof expanding throughout North America. All inquiries regarding the company, expansions and partnerships please email IR at investors@snakesandlattes.com.

4th QTR prediction from Chilidog on Stocktwits:

Chilidog1
Yesterday 1:13 PM

$FUNN End Fiscal Year 2023 tomorrow! Last QTR was $2.4m. 4th QTR 2022 was $1.75m. Shouldn't be to tuff to beat 4ht QTR 2022, but does the Q over Q winning streak continue? I say yes and predict $2.6m for 4th QTR 2023 with annual revenue at 9.3m. $FUNN
Bullish

PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA

June 27, 2023 - 7:00 am
Expected FDA approval for KETARX™ (racemic ketamine) via the ANDA pathway in Q1-2024 and commercial launch in Q2-2024

TORONTO, June 27, 2023 (GLOBE NEWSWIRE) -- PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has filed a Pre-Submission Facility Correspondence in advance of its Abbreviated New Drug Application (“ANDA”) for KETARX™ (racemic ketamine) to the Food and Drug Administration (“FDA”) to support expedited review of its priority ANDA. The filing of a Pre-Submission Facility Correspondence will help achieve approval early compared to the standard ANDA approval times. The Company anticipates KETARX™ approval from the FDA as early as Q1-2024 and commercial launch in the U.S. in Q2-2024 followed by the pursuit of international approvals to support the growing global demand for ketamine.

Ketamine is an essential medicine used for anesthesia and analgesia (pain relief) listed on the WHO Essential Medicines List. Ketamine has been on the FDA’s drug shortage list since February 2018. In Canada, ketamine has been classified as a Tier 3 drug shortage since February 2023, and Health Canada has approved ketamine for use as a sedative and painkiller in hospital settings. Outside of the FDA and Health Canada approved indications, ketamine is also being administered in hospitals and clinics to treat various disorders encompassing mental health, neurological and pain. A recently published new peer-reviewed study on the real-world effectiveness of ketamine intravenous therapy demonstrated significant patient improvement for depression, anxiety and suicidal ideation.

PharmaTher’s priority is to commercialize KETARX™ in the U.S. under ketamine’s FDA-approved label through its recently announced partnership with Vitruvias Therapeutics, Inc., a leading U.S. based specialty generic pharmaceutical company. The Company expects to market various dosage forms of KETARX™, such as 10 mg/ml, 50 mg/ml and 100 mg/ml, with the option to increase concentration and ready-to-administer applications for the U.S. and international markets.

About PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) develops and commercializes specialty pharmaceuticals exhibiting growing adoption and permitting novel delivery methods to enhance patient outcomes. The Company’s lead product is KETARX™ (racemic ketamine) to fill the global unmet medical needs for anesthesia, sedation, pain, mental health, and neurological indications. The Company is commercializing PharmaPatch™ (microneedle patch) with its partners to deliver psychedelics and drugs to treat infectious diseases. Learn more at PharmaTher.com.

For more information about PharmaTher, please contact:

Fabio Chianelli
Chief Executive Officer
PharmaTher Holdings Ltd.
Tel: 1-888-846-3171
Email: info@pharmather.com
Website: www.pharmather.com

You obviously have not done any DD on PharmaTher. Check it out!

Bullish case from Hattrick on Stocktwits

Hattrick3
16m
@Dirtymartini66 as frustrating as it’s been, this is far from over. No solutions are available, the Covid Therapeutic revenue projections are well over $30 billion in a few short years. Piles of money to be made. Start connecting the dots, the “sister” company Pharma Ther has just signed an agreement with Virtruvias Therapeutics out of Alabama. They have a CEO who has been in the business for decades and their Director worked for Johnson and Johnson for decades. They are also experts in the generic space. Phrrf is down the hall from Revive and they own a large chunk of Revive shares, enough to pay for their Ketarx trial when it launches if Revive can do something with Buci. Way too much money to be made and a drug that by every measurement has worked in every study that’s been done to date; trial data is coming. Is it possible that it doesn’t go any further; yep! Just not probable with the $$$ on the table for the company that has a Covid therapeutic; the drug works.
Bullish

PharmaTher Holdings Provides Corporate Update

https://www.bing.com/ck/a?!&&p=1efe6dd56f5e71aeJmltdHM9MTY4NjYxNDQwMCZpZ3VpZD0yMjMzYmY5OS0wZGM4LTZjYTgtMTI4Ny1hZDJmMGM1YjZkN2YmaW5zaWQ9NTE4Ng&ptn=3&hsh=3&fclid=2233bf99-0dc8-6ca8-1287-ad2f0c5b6d7f&psq=PharmaTher+Holdings+Provides+Corporate+Update&u=a1aHR0cHM6Ly93d3cuZ2xvYmVuZXdzd2lyZS5jb20vZW4vbmV3cy1yZWxlYXNlLzIwMjMvMDYvMTIvMjY4NjE1NS8wL2VuL1BoYXJtYVRoZXItSG9sZGluZ3MtUHJvdmlkZXMtQ29ycG9yYXRlLVVwZGF0ZS5odG1s&ntb=1

It ain't over yet! What everybody really loves is a good comeback kid story where the hero gets back up off the mat and never quits in spite of the pounding he receives from all the forces of evil knocking him down over and over again. And... in the end, the puny little battered guy eventually achieves his dream and conquers all! Call it a fantasy if you like, but that is the story we all really like! Stay tuned! Some of us have been here for over ten years and are still hanging in there!

Havn't seen 7 since January!

Nice close! Up 40%!

BIEL hit 7!